Effects of Nasal-spraying LiveSpo Navax in Treatment of Acute Respiratory Infections in Children
Acute Respiratory Tract Infections
About this trial
This is an interventional treatment trial for Acute Respiratory Tract Infections focused on measuring Respiratory Syncytial Virus (RSV), Acute Respiratory Tract Infections (ARTIs), Children, Nasal-spraying probiotics, Viral load, Co-infection bacteria, Cytokines, Bacillus spores
Eligibility Criteria
Inclusion Criteria:
- Children (male/female) aged from 4 to 60 months.
- Admitted hospital due to lower respiratory infection.
- RSV is positive by rapid test.
- Parents of the pediatric patient agree to participate in the study, explain and sign the research consent form.
Exclusion Criteria:
- Newborn babies.
- Have a history of drug allergy.
- Need oxygen therapy.
- Discharged before day 3.
- Lost to follow-up.
- Withdrawn from the trial.
- Continuing in the trial but missing data.
- Meeting the criteria for psychiatric disorders other than depression and/or anxiety.
Sites / Locations
- International Center, Vietnam National Children's Hospital
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Control
Navax
Control group receives the routine treatment and uses 0.9% NaCl physiological saline: Routine treatment is as follows: Oral administrative drugs: antipyretic paracetamol (Efferegant®️); anti-inflammatory corticosteroid methylprednisolon; antibiotics e.g. ampicillin and sulbactam complex (Ama-power®️), tobramycin (Medphatobra®️), or cefotaxim (Goldcefo®️), based on the results of antibiotic susceptibility test. Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin ®️inhaler) or budesonide (Pulmicort ®️Respules).
Navax group receives the routine treatment and uses NaCl 0.9% plus B. subtilis and B. clausii at 5 billions CFU/5 mL (LiveSpo®️ Navax): Routine treatment is as follows: Oral administrative drugs: antipyretic paracetamol (Efferegant®️); anti-inflammatory corticosteroid methylprednisolon; antibiotics e.g. ampicillin and sulbactam complex (Ama-power®️), tobramycin (Medphatobra®️), or cefotaxim (Goldcefo®️), based on the results of antibiotic susceptibility test. Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin ®️inhaler) or budesonide (Pulmicort ®️Respules).